

Appendix Table 1b. *Lifetime comorbidities of Generalized Anxiety Disorder with other anxiety, mood, and substance use disorders, in the MHS-OHS (Canada)*

	Temporal Priority of GAD and Comorbid Disorder†								
	Lifetime Generalized Anxiety Disorder			Lifetime GAD First		Comorbid Disorder First		Both Started in Same Year	
	%	OR‡	(95% CI)	%	(se)	%	(se)	%	(se)
I. Anxiety disorders									
Agoraphobia	34.2§	9.2*	(5.0-16.8)	11.5	(4.0)	44.2	(16.5)	44.3	(14.9)
Panic disorder	24.4	27.6*	(17.7-43.1)	20.9	(12.5)	13.8	(10.7)	65.3	(14.6)
Simple phobia	34.2	6.4*	(3.1-13.0)	3.2	(1.4)	66.6	(10.3)	30.3	(10.6)
Social phobia	47.7	6.5*	(4.4-9.6)	15.6	(8.7)	65.0	(12.3)	19.3	(8.8)
Any anxiety disorder	69.7	9.2*	(5.9-14.5)	20.0	(6.9)	74.3	(7.1)	33.8	(6.7)
II. Mood disorders									
Dysthymia	37.6	25.4*	(16.7-38.8)	25.0	(5.6)	25.7	(13.9)	49.3	(14.2)
Major depression	61.4	20.4*	(14.5-29.4)	16.7	(4.7)	31.5	(10.0)	51.8	(10.3)
Mania	8.0	10.7*	(4.6-24.8)	47.2	(24.8)	20.6	(12.1)	32.2	(18.2)
Any mood disorder	66.7	21.0*	(14.8-29.8)	27.3	(3.6)	33.1	(9.4)	56.5	(9.3)
III. Substance use disorders									
Substance abuse	39.6	3.0*	(1.7-5.2)	43.5	(8.5)	57.6	(8.9)	2.4	(1.5)
Substance dependence	33.7	5.0*	(3.0-8.4)	63.1	(9.2)	20.3	(10.9)	16.6	(14.3)
Any substance use disorder	41.9	3.1	(1.8-5.4)	59.2	(6.8)	55.4	(8.5)	15.4	(12.1)
IV. Any disorder	87.9	12.4*	(7.4-2.1)	45.3	(6.5)	80.0	(3.8)	59.0	(5.2)

* p<0.05

† All percentages were calculated in the subsample of respondents who had both disorders.

‡ Results in this column are based on logistic regression coefficients estimated in a series of separate models to predict lifetime GAD in Canada. For example, the odds of having GAD are 9.2 times as great among respondents with a history of lifetime agoraphobia as those without lifetime agoraphobia.

§ 34.2% of people in Canada with lifetime GAD had agoraphobia in their lifetime.

|| Substances include alcohol, cocaine, inhalants, marijuana, hashish, opiates, psychedelics, sedatives, and stimulants.